Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
4.960
+0.190 (3.98%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Unicycive Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 44.19 | 29.2 | 26.14 | 9.7 | 0.46 | 16.58 |
Short-Term Investments | 17.24 | 12.07 | - | - | - | - |
Cash & Short-Term Investments | 61.43 | 41.27 | 26.14 | 9.7 | 0.46 | 16.58 |
Cash Growth | 175.12% | 57.87% | 169.48% | 2032.09% | -97.26% | - |
Prepaid Expenses | 7.63 | 6.52 | 3.87 | 3.37 | 2.03 | 1.71 |
Other Current Assets | 2.27 | 1.17 | 0.94 | 0.33 | 0.16 | 0.13 |
Total Current Assets | 71.32 | 48.96 | 30.95 | 13.4 | 2.64 | 18.41 |
Property, Plant & Equipment | 0.71 | 0.17 | 0.72 | 0.79 | 0.17 | 0.33 |
Total Assets | 72.03 | 49.14 | 31.67 | 14.19 | 2.82 | 18.74 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.23 | 0.38 | 1.06 | 0.84 | 0.89 | 0.74 |
Accrued Expenses | 2.14 | 1.52 | 3.56 | 3.23 | 2.24 | 1.21 |
Current Portion of Leases | 0.62 | 0.12 | 0.56 | 0.33 | 0.16 | 0.15 |
Other Current Liabilities | 13.72 | 16.92 | 18.94 | 13.13 | - | - |
Total Current Liabilities | 18.7 | 18.94 | 24.12 | 17.53 | 3.28 | 2.11 |
Long-Term Leases | 0.06 | - | 0.12 | 0.47 | - | 0.16 |
Total Liabilities | 18.76 | 18.94 | 24.24 | 18 | 3.28 | 2.26 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.03 | 0.02 | 0.01 | 0.04 | 0.02 | 0.02 |
Additional Paid-In Capital | 195.64 | 158 | 108.69 | 60.7 | 33.52 | 32.41 |
Retained Earnings | -142.37 | -127.83 | -101.27 | -64.54 | -34 | -15.94 |
Comprehensive Income & Other | -0.02 | -0 | - | - | - | - |
Shareholders' Equity | 53.27 | 30.2 | 7.43 | -3.81 | -0.47 | 16.48 |
Total Liabilities & Equity | 72.03 | 49.14 | 31.67 | 14.19 | 2.82 | 18.74 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.67 | 0.12 | 0.68 | 0.79 | 0.16 | 0.31 |
Net Cash (Debt) | 60.75 | 41.15 | 25.46 | 8.91 | 0.3 | 16.27 |
Net Cash Growth | 177.19% | 61.63% | 185.82% | 2869.33% | -98.16% | - |
Net Cash Per Share | 2.69 | 2.59 | 3.80 | 3.63 | 0.20 | 13.94 |
Filing Date Shares Outstanding | 27.86 | 25.24 | 11.97 | 3.48 | 1.52 | 1.5 |
Total Common Shares Outstanding | 27.86 | 22.11 | 11.38 | 3.48 | 1.52 | 1.5 |
Working Capital | 52.62 | 30.02 | 6.83 | -4.14 | -0.64 | 16.31 |
Book Value Per Share | 1.91 | 1.37 | 0.65 | -1.10 | -0.31 | 10.99 |
Tangible Book Value | 53.27 | 30.2 | 7.43 | -3.81 | -0.47 | 16.48 |
Tangible Book Value Per Share | 1.91 | 1.37 | 0.65 | -1.10 | -0.31 | 10.99 |
Machinery | 0.07 | 0.07 | 0.07 | 0.02 | 0.01 | 0.01 |
Leasehold Improvements | 0.04 | 0.07 | 0.05 | 0.02 | 0.02 | 0.02 |